281 results on '"Wu, Chao-Liang"'
Search Results
252. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.
- Author
-
Huang TH, Kuo CW, Chen CW, Tseng YL, Wu CL, and Lin SH
- Subjects
- Aged, Aged, 80 and over, Biomarkers blood, Female, Humans, Idiopathic Pulmonary Fibrosis blood, Male, Prognosis, Proportional Hazards Models, Retrospective Studies, Idiopathic Pulmonary Fibrosis drug therapy, Indoles therapeutic use, Mucin-1 blood, Pulmonary Surfactant-Associated Protein A blood
- Abstract
Background: Nintedanib is effective for treating idiopathic pulmonary fibrosis (IPF), but some patients may exhibit a suboptimal response and develop on-treatment acute exacerbation (AE-IPF), hepatic injury, or mortality. It remains unclear which patients are at risk for these adverse outcomes., Methods: We analysed the demographic and clinical data, baseline plasma levels of Krebs von den Lungen-6 (KL-6) and surfactant protein A (SPA), and longitudinal clinical courses of a real-world cohort of IPF patients who received nintedanib ≥ 14 days between March 2017 and December 2020. Cox proportional-hazards regression, subdistribution hazards regression, and sensitivity analyses were performed to investigate the association between baseline predictors and AE-IPF, mortality, and nintedanib-related hepatic injury. The relationship between baseline predictors and pulmonary function decline was determined., Results: Fifty-seven patients were included, of whom 24 (42%) developed hepatic injury, 20 (35%) had AE-IPF, and 16 (28%) died on-treatment. A baseline plasma KL-6 level ≥ 2.5 ng/mL, and diffusion capacity for carbon monoxide (D
LCO ) < 55% predicted, were associated with increased risk of hepatic injury (adjusted hazard ratio [aHR] was 3.46; 95% CI 1.13-10.60; p = 0.029 for KL-6, and 6.05; 95% CI 1.89-19.32; p = 0.002 for DLCO ). Both factors also predicted severe and recurrent hepatic injury. Patients with baseline KL-6 ≥ 2.5 ng/mL also had a higher risk of AE-IPF (aHR 4.52; 95% CI 1.63-12.55; p = 0.004). For on-treatment mortality, baseline KL-6 ≥ 3.5 ng/mL and SPA ≥ 600 pg/mL were significant predictors (aHR 5.39; 95% CI 1.16-24.97; p = 0.031 for KL-6, and aHR 12.28; 95% CI 2.06-73.05; p = 0.006 for SPA). Results from subdistribution hazard regression and sensitivity analyses supported these findings. Patients with elevated baseline plasma KL-6 levels also exhibited a trend towards faster pulmonary function decline., Conclusions: For patients with IPF who are receiving nintedanib, we have identified baseline predictors, in particular plasma KL-6 levels, for the risk of adverse outcomes. Patients with these predictors may require close monitoring for unfavourable responses during treatment. Our findings also support the prognostic role of molecular markers like KL-6 and may contribute to future formulation of more individualized therapeutic strategies for IPF.- Published
- 2021
- Full Text
- View/download PDF
253. Up-Regulated Expression of Pro-Apoptotic Long Noncoding RNA lincRNA-p21 with Enhanced Cell Apoptosis in Lupus Nephritis.
- Author
-
Chen YC, Kuo PY, Chou YC, Chong HE, Hsieh YT, Yang ML, Wu CL, Shiau AL, and Wang CR
- Subjects
- Animals, Case-Control Studies, Cell Line, Disease Models, Animal, Humans, Immunohistochemistry, Lupus Erythematosus, Systemic genetics, Lupus Nephritis metabolism, Lupus Nephritis pathology, Mice, RNA Interference, Severity of Illness Index, T-Lymphocytes immunology, T-Lymphocytes metabolism, Transcriptional Activation, Up-Regulation, Apoptosis genetics, Gene Expression Regulation, Lupus Nephritis etiology, RNA, Long Noncoding genetics
- Abstract
Accelerated cell apoptosis with dysregulated long noncoding RNAs is the crucial pathogenesis in lupus nephritis (LN). Pro-apoptotic lincRNA-p21 was studied in LN patients, cell lines with lentivirus-mediated overexpression and CRISPR interference (CRISPRi)-conducted repression, and a mouse model. Clinical samples were from patients and age/sex-matched controls. Expression of lincRNA-p21 and endogenous RNA target miR-181a, were examined in mononuclear and urine cells. Guide RNA sequences targeting lincRNA-p21 were cloned into CRISPRi with dCas9/ Krüppel-associated box (KRAB) domain. LincRNA-p21-silened transfectants were investigated for apoptosis and miR-181a expression. LincRNA-p21-overexpressed cells were evaluated for apoptosis and p53-related down-stream molecules. Balb/C mice were injected with pristane to induce LN and examined for apoptosis and lincRNA-p21. Higher lincRNA-p21 levels were found in LN mononuclear and urine cells, positively correlated with activity. There were lower miR-181a levels in LN mononuclear cells, negatively correlated with activity. Doxorubicin-induced apoptotic cells had up-regulated lincRNA-p21 levels. CRISPRi with dCas9/KARA domain showed efficient repression ability on transcription initiation/elongation. CRISPRi-conducted lincRNA-p21-silenced transfectants displayed reduced apoptosis with up-regulated miR-181a levels, whereas lentivirus-mediated lincRNA-p21-overexpressed cells revealed enhanced apoptosis with up-regulated downstream PUMA/Bax expression. LN mice had glomerular apoptosis with progressive increased lincRNA-p21 levels. Our results demonstrate up-regulated lincRNA-p21 expression in LN, implicating a potential diagnostic marker and therapeutic target.
- Published
- 2020
- Full Text
- View/download PDF
254. Prothymosin α activates type I collagen to develop a fibrotic placenta in gestational diabetes.
- Author
-
Wu HT, Kang L, Su YC, Ou HY, Chan FY, Chen YC, Su BH, Wang YS, Wu CL, Shiau AL, and Wu P
- Subjects
- Adult, Animals, Diabetes, Gestational genetics, Female, Fibrosis, Gene Expression Regulation, Humans, Hyperglycemia complications, Inflammation pathology, Mice, Inbred C57BL, Mice, Transgenic, NF-kappa B metabolism, Pregnancy, Reactive Oxygen Species metabolism, Signal Transduction, Thymosin metabolism, Trophoblasts metabolism, Collagen Type I metabolism, Diabetes, Gestational metabolism, Diabetes, Gestational pathology, Placenta pathology, Protein Precursors metabolism, Thymosin analogs & derivatives
- Abstract
High-risk pregnancies, such as pregnancies with gestational diabetes mellitus (GDM), are becoming more common and as such, have become important public health issues worldwide. GDM increases the risks of macrosomia, premature infants, and preeclampsia. Although placental dysfunction, including fibrosis is associated with the development of GDM, factors that link these observations remain unknown. Prothymosin α (ProTα) is expressed in the placenta and is involved in cell proliferation and immunomodulation. It also plays an important role in insulin resistance and fibrosis. However, the role of ProTα in GDM is still unclear. In the present study, we found that fibrosis-related protein expressions, such as type I collagen (Col-1) were significantly increased in the placentae of ProTα transgenic mice. With elevated fibrosis-related protein expressions, placental weights significantly increased in GDM group. In addition, placental and circulating ProTα levels were significantly higher in patients with GDM (n=39), compared with the healthy group (n=102), and were positively correlated with Col-1 expression. Mice with streptozotocin (STZ)-induced GDM had increased ProTα, fasting blood glucose, Col-1, and placental weight, whereas plasma insulin levels were decreased. ProTα overexpression enhanced nuclear factor κB (NFκB) activation to increase fibrosis-related protein expressions in 3A-Sub-E trophoblasts, while treatment with an NFκB inhibitor reversed the effect of ProTα on fibrosis-related protein expressions. We further investigated whether ProTα is regulated by hyperglycemia-induced reactive oxygen species (ROS). In conclusion, ProTα increases the amount of placental connective tissue and thus contributes to the pathogenesis of placental fibrosis in GDM. Therefore, ProTα may be a novel therapeutic target for GDM., (© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.)
- Published
- 2020
- Full Text
- View/download PDF
255. Role of placental fibrinogen-like protein 1 in gestational diabetes.
- Author
-
Kang L, Li HY, Ou HY, Wu P, Wang SH, Chang CJ, Lin SY, Wu CL, and Wu HT
- Subjects
- Adult, Female, Fibrinogen physiology, Gluconeogenesis physiology, Humans, Pregnancy, Diabetes, Gestational metabolism, Fibrinogen metabolism, Placenta metabolism
- Abstract
In view of the increasing prevalence of gestational diabetes mellitus (GDM) and the increased risks of delivering a macrosomic infant, developing preeclampsia, and suffering a perinatal death due to GDM, GDM has emerged as a growing public health problem. Although the placenta was suggested to play a crucial role in the pathology of GDM, the mechanisms that induce the development of GDM are still obscure. Fibrinogen-like protein (FGL)-1 is a hepatokine that plays an important role in hepatogenesis, as well as in nonalcoholic fatty liver disease and diabetes. Although FGL-1 is also expressed by the placenta, the pathophysiological role of FGL-1 in GDM is still unknown. In this study, FGL-1 levels were evaluated in 45 subjects with (n = 16) or without (n = 29) GDM. We found that FGL-1 was mainly expressed by placental trophoblasts, and FGL-1 expression was significantly higher in subjects with GDM. FGL-1 increased trophoblast proliferation through an extracellular signal-regulated kinase 1/2-dependent pathway. In addition, plasma concentrations of FGL-1 were higher in subjects with GDM, and the increased circulating FGL-1 might contribute to systemic insulin resistance. FGL-1 disrupted the gluconeogenic action of insulin in HepG2 cells, and decreased insulin-induced glucose uptake by L6 myotubes. Taken together, placental FGL-1 possibly plays a role in the impairment of insulin function in the development of GDM, and it might be a novel biomarker for diagnosing GDM., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
256. Retraction: Kuo, W.S. et al. Amelioration of Experimentally Induced Arthritis by Reducing Reactive Oxygen Species Production through the Intra-Articular Injection of Water-Soluble Fullerenol. Nanomaterials 2019, 9, 909.
- Author
-
Wen-ShuoKuo, Chia-TseWeng, Chen JH, Wu CL, Shiau AL, Hsieh JL, So EC, Wu PT, and Chen SY
- Abstract
One of the contributors to the published paper [1] did not provide permission for the datapresented to be published and we have therefore taken the decision to retract the paper [...].
- Published
- 2020
- Full Text
- View/download PDF
257. Inhibition of CD44 induces apoptosis, inflammation, and matrix metalloproteinase expression in tendinopathy.
- Author
-
Wu PT, Su WR, Li CL, Hsieh JL, Ma CH, Wu CL, Kuo LC, Jou IM, and Chen SY
- Subjects
- Actins genetics, Actins metabolism, Animals, Antibodies immunology, Cells, Cultured, Cyclooxygenase 2 genetics, Cyclooxygenase 2 metabolism, Humans, Hyaluronan Receptors genetics, Hyaluronan Receptors immunology, Male, Matrix Metalloproteinases genetics, Rats, Rats, Sprague-Dawley, Signal Transduction drug effects, Silicon Dioxide toxicity, Tendinopathy metabolism, Tendinopathy pathology, Tenocytes cytology, Tenocytes metabolism, Tumor Necrosis Factor-alpha genetics, Tumor Necrosis Factor-alpha metabolism, Apoptosis drug effects, Hyaluronan Receptors metabolism, Inflammation Mediators metabolism, Matrix Metalloproteinases metabolism
- Abstract
Apoptosis has emerged as a primary cause of tendinopathy. CD44 signaling pathways exert anti-apoptotic and -inflammatory effects on tumor cells, chondrocytes, and fibroblast-like synoviocytes. The aim of this study was to examine the association among CD44, apoptosis, and inflammation in tendinopathy. Expression of CD44 and apoptotic cell numbers in tendon tissue from patients with long head of biceps (LHB) tendinopathy were determined according to the histological grades of tendinopathy. Primary tenocytes from Achilles tendon of Sprague-Dawley rats 1 week after collagenase injection were cultured with an antagonizing antibody against CD44. Treatment responses were determined by evaluating cell viability and expression of tendon-related proliferation markers, inflammatory mediators, and apoptosis. The expression of CD44 and apoptosis were positively correlated with the severity of tendinopathy in the human LHB tendinopathy. Furthermore, CD44 expression and apoptotic cells were co-stained in tendinopathic tendon. Blocking the CD44 signaling pathways in rat primary tenocytes by OX-50 induced cell apoptosis and the elevated levels of cleaved caspase-3. Furthermore, they had decreased cell viability and expression of collagen type I, type III, tenomodulin, and phosphorylated AKT. In contrast, there were elevated levels of inflammatory mediators, including interleukin (IL)-1β, IL-6, tumor necrosis factor-α, cyclooxygenase-2, and phosphorylated NF-κB, as well as matrix metalloproteinase (MMP) family members including MMP-1, -3, -9, and -13 in tenocytes upon OX-50 treatment. This study is the first to demonstrate the association of CD44 and apoptosis in tendinopathy. Our data imply that CD44 may play a role in tendinopathy via regulating apoptosis, inflammation, and extracellular matrix homeostasis., (© 2019 Wu et al.)
- Published
- 2019
- Full Text
- View/download PDF
258. Prothymosin α promotes STAT3 acetylation to induce cystogenesis in Pkd1-deficient mice.
- Author
-
Chen YC, Su YC, Shieh GS, Su BH, Su WC, Huang PH, Jiang ST, Shiau AL, and Wu CL
- Subjects
- Acetylation, Animals, Disease Progression, Dogs, HEK293 Cells, Humans, Madin Darby Canine Kidney Cells, Mice, Mice, Knockout, Polycystic Kidney Diseases metabolism, Protein Precursors genetics, Thymosin genetics, Thymosin physiology, Polycystic Kidney Diseases pathology, Protein Precursors physiology, STAT3 Transcription Factor metabolism, TRPP Cation Channels genetics, Thymosin analogs & derivatives
- Abstract
Polycystic kidney disease (PKD) is characterized by the expansion of fluid-filled cysts in the kidney, which impair the function of kidney and eventually leads to end-stage renal failure. It has been previously demonstrated that transgenic overexpression of prothymosin α (ProT) induces the development of PKD; however, the underlying mechanisms remain unclear. In this study, we used a mouse PKD model that sustains kidney-specific low-expression of Pkd1 to illustrate that aberrant up-regulation of ProT occurs in cyst-lining epithelial cells, and we further developed an in vitro cystogenesis model to demonstrate that the suppression of ProT is sufficient to reduce cyst formation. Next, we found that the expression of ProT was accompanied with prominent augmentation of protein acetylation in PKD, which results in the activation of downstream signal transducer and activator of transcription (STAT) 3. The pathologic role of STAT3 in PKD has been previously reported. We determined that this molecular mechanism of protein acetylation is involved with the interaction between ProT and STAT3; consequently, it causes the deprivation of histone deacetylase 3 from the indicated protein. Conclusively, these results elucidate the significant role of ProT, including protein acetylation and STAT3 activation in PKD, which represent potential for ameliorating the disease progression of PKD.-Chen, Y.-C., Su, Y.-C., Shieh, G.-S., Su, B.-H., Su, W.-C., Huang, P.-H., Jiang, S.-T., Shiau, A.-L., Wu, C.-L. Prothymosin α promotes STAT3 acetylation to induce cystogenesis in Pkd1-deficient mice.
- Published
- 2019
- Full Text
- View/download PDF
259. In vivo expression of thrombospondin-1 suppresses the formation of peritoneal adhesion in rats.
- Author
-
Tai YS, Jou IM, Jung YC, Wu CL, Shiau AL, and Chen CY
- Abstract
Background: Formation of intraperitoneal adhesions is one of the major complications after abdominal surgery, which may lead to bowel obstruction. Thrombospondin 1 (TSP-1) is an extracellular matrix modulating glycoprotein during tissue regeneration and collagen deposition., Aim: To evaluated the therapeutic potential of overexpressed TSP-1 in suppressing pelvic adhesion formations in rat models., Methods: Pelvic adhesion was induced in anesthetized rats by laparotomy cecal abrasion. The animals were randomly assigned to treatment of local application with Seprafilm (an antiadhesive bioresorbable membrane) or adenoviral vectors encoding mouse TSP-1 (AdTSP-1) on the surfaces of the injured cecum. The severity of the peritoneal adhesions was evaluated by blinded observers 14 d later., Results: Compared with control (no treatment) group, the application of Sperafilm significantly reduced the formation of adhesion band, and local administration of AdTSP-1 on the injured cecum the also attenuated the severity of peritoneal adhesion score. However, systemic delivery of AdTSP-1 did not affect the formation of adhesion., Conclusion: We conclude that therapeutic approaches in inducing regional overexpression of TSP-1 may serve as alternative treatment strategies for preventing postoperative peritoneal adhesion., Competing Interests: Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
- Published
- 2019
- Full Text
- View/download PDF
260. One-dimensional poly(L-lysine)-block-poly(L-threonine) assemblies exhibit potent anticancer activity by enhancing membranolysis.
- Author
-
Chen YF, Shiau AL, Chang SJ, Fan NS, Wang CT, Wu CL, and Jan JS
- Subjects
- A549 Cells, Animals, Cell Line, Tumor, Humans, Lung Neoplasms metabolism, Lung Neoplasms pathology, Mice, Mitochondrial Membranes pathology, Neoplasms, Experimental metabolism, Neoplasms, Experimental pathology, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents pharmacology, Cell-Penetrating Peptides chemistry, Cell-Penetrating Peptides pharmacokinetics, Cell-Penetrating Peptides pharmacology, Cisplatin chemistry, Cisplatin pharmacokinetics, Cisplatin pharmacology, Lung Neoplasms drug therapy, Mitochondrial Membranes metabolism, Neoplasms, Experimental drug therapy, Polylysine chemistry, Polylysine pharmacokinetics, Polylysine pharmacology
- Abstract
Herein, we report the oncolytic activity of cationic, one-dimensional (1D) fibril assemblies formed from coil-sheet poly(L-lysine)-block-poly(L-threonine) (PLL-b-PLT) block copolypeptides for cancer therapy. The 1D fibril assemblies can efficiently interact with negatively charged cellular and mitochondrial membranes via electrostatic interactions, leading to necrosis via membrane lysis and apoptosis via the mitochondria-lytic effect. The concept is analogous to that of 1D drug carriers that exhibit enhanced cell penetration. In comparison to free PLL chains, PLL-b-PLT fibril assemblies exhibit selective cytotoxicity toward cancer cells, low hemolysis activity, enhanced membranolytic activity, and a different apoptosis pathway, which may be due to differences in the peptide-membrane interactions. Antitumor studies using a metastatic LL2 lung carcinoma model indicate that the fibril assemblies significantly inhibited tumor growth, improved survival in tumor-bearing mice and suppressed lung metastasis without obvious body weight loss. An additive efficacy was also observed for treatment with both PLL-b-PLT and cisplatin. These results support the feasibility of using 1D fibril assemblies as potential apoptotic anticancer therapeutics., Statement of Significance: We report that cationic, one-dimensional (1D) fibril assemblies formed by coil-sheet poly(L-lysine)-block-poly(L-threonine) (PLL-b-PLT) block copolypeptides exhibited potent anticancer activity by enhancing membranolysis. The 1D fibril assemblies can efficiently interact with negatively charged cellular and mitochondrial membranes via electrostatic interactions, leading to necrosis via membrane lysis and apoptosis via mitochondria-lytic effect. Moreover, the fibril assemblies exhibited low hemolytic activity and selective cytotoxicity toward cancer cell, which is advantageous as compared to PLL and most antimicrobial/anticancerous peptides. This study provides a new concept of using cationic, 1D fibril assemblies for cancer therapy., (Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
261. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.
- Author
-
Lu CS, Shieh GS, Wang CT, Su BH, Su YC, Chen YC, Su WC, Wu P, Yang WH, Shiau AL, and Wu CL
- Subjects
- Animals, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Cell Line, Tumor, Cisplatin pharmacology, Cisplatin therapeutic use, Disease Models, Animal, Drug Synergism, Gene Knockdown Techniques, Humans, Hyaluronan Receptors metabolism, Mice, Neoplasm Grading, Neoplasm Recurrence, Local, Neoplasm Staging, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms pathology, Xenograft Model Antitumor Assays, Drug Resistance, Neoplasm genetics, Gene Expression Regulation, Neoplastic drug effects, Octamer Transcription Factor-3 genetics, Urinary Bladder Neoplasms genetics
- Abstract
Cancer cells initially characterized as sensitive to chemotherapy may acquire resistance to chemotherapy and lead to tumor recurrence through the expansion of drug-resistant population. Acquisition of drug resistance to conventional chemotherapy is a major obstacle in the treatment of recurrent cancer. Here we investigated whether anticancer drugs induced Oct4 expression, thereby contributing to acquired drug resistance and tumor recurrence in bladder cancer. We identified a positive correlation of Oct4 expression with tumor recurrence in 122 clinical specimens of superficial high-grade (stages T1-2) bladder transitional cell carcinoma (TCC). Increased Oct4 levels in bladder tumors were associated with short recurrence-free intervals in the patients. Chemotherapy induced Oct4 expression in bladder cancer cells. Notably, treatment with cisplatin increased CD44-positive bladder cancer cells expressing Oct4, representing cancer stem-like cell subpopulation. Forced expression of Oct4 reduced, whereas knockdown of Oct4 enhanced, drug sensitivity in bladder cancer cells. Furthermore, tumor cells overexpressing Oct4 responded poorly to cisplatin in vivo. In regard to clinical relevance, inhibition of Oct4 by all-trans retinoic acid (ATRA) synergistically increased sensitivity to cisplatin in bladder cancer cells. Furthermore, the combination of cisplatin and ATRA was superior to cisplatin alone in suppressing tumor growth. Therefore, our results provide evidence that Oct4 increases drug resistance and implicate that inhibition of Oct4 may be a therapeutic strategy to circumvent drug resistance.
- Published
- 2017
- Full Text
- View/download PDF
262. Deletion of Nuclear Localizing Signal Attenuates Proinflammatory Activity of Prothymosin-Alpha and Enhances Its Neuroprotective Effect on Transient Ischemic Stroke.
- Author
-
Wang LC, Wu CL, Cheng YY, and Tsai KJ
- Subjects
- Animals, Ischemic Attack, Transient genetics, Ischemic Attack, Transient prevention & control, Male, Nuclear Localization Signals genetics, Protein Precursors genetics, Rats, Rats, Sprague-Dawley, Stroke genetics, Stroke prevention & control, Thymosin genetics, Thymosin therapeutic use, Treatment Outcome, Gene Deletion, Ischemic Attack, Transient metabolism, Neuroprotective Agents therapeutic use, Nuclear Localization Signals deficiency, Protein Precursors therapeutic use, Stroke metabolism, Thymosin analogs & derivatives
- Abstract
Post-ischemic inflammation plays an important role in the progression of ischemia/reperfusion injuries. Prothymosin-α (ProT) can protect cells from necrotic death following ischemia; however, its immunostimulatory actions may counteract the neuroprotective effect. We proposed that ProTΔNLS, synthesized by deleting its nuclear localizing signal (NLS) at the C-terminal of ProT, can attenuate the immunostimulatory activity and has more salient neuroprotective effect. In this study, we examined the therapeutic effects of ProT and ProTΔNLS in a transient middle cerebral artery occlusion (tMCAO) model of rats. Rats that had sustained 90 min of tMCAO were treated with GST-vehicle, ProT, or ProTΔNLS. Therapeutic outcomes were evaluated by infarction volume assay and behavioral assessment. Changes to inflammatory mediators, including tumor necrosis factor α (TNF-α), interleukin-10 (IL-10), and myeloperoxidase (MPO) were evaluated by enzyme-linked immunosorbent assay. Activated matrix metalloproteinases 2 (MMP-2) and 9 (MMP-9) levels were evaluated by gelatin zymography. Microglial activation was identified by double-immunostaining for Iba-1 and CD68. Our results showed that while both ProT and ProTΔNLS reduce infarction volume and improve functional outcome, ProTΔNLS provides the best therapeutic outcome. ProT increases TNF-α but decreases IL-10 secretion after ischemic injury, reflecting its pro-inflammatory activity. ProTΔNLS suppresses expression of TNF-α, MPO, and activity of MMPs in ischemic brain tissue. It also suppresses activation of microglia in penumbral cortex. These data demonstrate the immunesuppressive activities of ProTΔNLS. In conclusion, ProT has pro-inflammatory effect that may counteract its neuroprotective effect. Deletion of NLS from ProT may attenuate post-ischemic inflammation and enhance the neuroprotective effects of ProT.
- Published
- 2017
- Full Text
- View/download PDF
263. A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes.
- Author
-
Wu HT, Ou HY, Hung HC, Su YC, Lu FH, Wu JS, Yang YC, Wu CL, and Chang CJ
- Subjects
- Aged, Animals, Blood Glucose metabolism, Cross-Sectional Studies, Diabetes Mellitus, Type 2 genetics, Female, Fibrinogen, Glucose Intolerance genetics, Hep G2 Cells, Humans, Insulin metabolism, Insulin Resistance genetics, Male, Mice, Mice, Inbred C57BL, Middle Aged, Neoplasm Proteins genetics, Diabetes Mellitus, Type 2 metabolism, Insulin Resistance physiology, Neoplasm Proteins metabolism
- Abstract
Aims/hypothesis: Type 2 diabetes is highly correlated with nonalcoholic fatty liver disease (NAFLD). Hepatocyte-derived fibrinogen-related protein 1 (HFREP1) is a hepatokine that mediates NAFLD development; however, the role of HFREP1 in the development of insulin resistance and diabetes remains obscure., Methods: A total of 193 age- and sex-matched participants with normal glucose tolerance, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and newly diagnosed diabetes (NDD) were recruited for a cross-sectional study. Plasma HFREP1 levels were measured and multivariate linear regression analysis was used to evaluate the relationship between HFREP1, IFG, IGT and NDD. The causal relationship between HFREP1 and insulin resistance was then investigated in animal and cell models. Glucose and insulin tolerance tests, and euglycaemic-hyperinsulinaemic clamp, were used to evaluate insulin sensitivity in animals with Hfrep1 overexpression or knockdown in liver by lentiviral vectors. HepG2 cells were used to clarify the possible mechanism of HFREP1-induced insulin resistance., Results: Plasma HFREP1 concentrations were significantly increased in participants with IFG, IGT and NDD. HFREP1 concentrations were independently associated with fasting plasma glucose levels, insulin resistance, IFG, IGT and NDD. Injection of recombinant HFREP1 or Hfrep1 overexpression induced insulin resistance in mice, and HFREP1 disrupted insulin signalling to induce insulin resistance through an extracellular signal-regulated kinase (ERK)1/2-dependent pathway. Moreover, hepatic knockdown of HFREP1 improved insulin resistance in both mice fed a high-fat diet and ob/ob mice., Conclusions/interpretation: These findings highlight the crucial role of HFREP1 in insulin resistance and diabetes, and provide a potential strategy and biomarker for developing therapeutic approaches to combat these diseases.
- Published
- 2016
- Full Text
- View/download PDF
264. Over-expression of prothymosin-α antagonizes TGFβ signalling to promote the development of emphysema.
- Author
-
Su BH, Tseng YL, Shieh GS, Chen YC, Wu P, Shiau AL, and Wu CL
- Subjects
- Acetylation, Animals, Case-Control Studies, Cells, Cultured, Disease Models, Animal, Down-Regulation physiology, Histone Deacetylases metabolism, Humans, Male, Matrix Metalloproteinases metabolism, Mice, Mice, Transgenic, Signal Transduction physiology, Smad7 Protein metabolism, Thymosin metabolism, Tissue Inhibitor of Metalloproteinase-3 genetics, Tissue Inhibitor of Metalloproteinase-3 metabolism, Transcription, Genetic genetics, Protein Precursors metabolism, Pulmonary Emphysema etiology, Thymosin analogs & derivatives, Transforming Growth Factor beta antagonists & inhibitors
- Abstract
Emphysema, a major consequence of chronic obstructive pulmonary disease (COPD), is characterized by the permanent airflow restriction resulting from enlargement of alveolar airspace and loss of lung elasticity. Transforming growth factor-β (TGFβ) signalling regulates the balance of matrix metalloproteinase (MMP)/tissue inhibitor of matrix metalloproteinase (TIMP) to control matrix homeostasis. Patients with COPD have dysregulated TGFβ signalling and reduced histone deacetylase (HDAC) activity through epigenetic up-regulation of histone acetylation in the promoters of pro-inflammatory genes. However, the potential link between decreased HDAC activity and dysregulated TGFβ signalling in emphysema pathogenesis remains to be determined. Prothymosin α (ProT), a highly conserved acidic nuclear protein, plays a role in the acetylation of histone and non-histone proteins. The aim of this study was to test the hypothesis that ProT inhibits TGFβ-Smad signalling through Smad7, thereby contributing to emphysema pathogenesis. We show that ProT enhances Smad7 acetylation by decreasing its association with HDAC and thereby down-regulates TGFβ-Smad signalling. ProT caused an imbalance between MMP and TIMP through acetylated Smad7 in favour of MMP expression. In addition to interfering with R-Smad activation and targeting receptors for degradation in the cytoplasm, acetylated Smad7 potentiated by ProT competitively antagonized binding of the pSmad2/3-Smad4 complex to the TIMP-3 promoter, resulting in reduced TIMP-3 expression. These effects were detected in ProT-over-expressing cells, lungs of ProT transgenic mice displaying an emphysema phenotype and in emphysema patients. Importantly, increased Smad7 and reduced TIMP-3 were found in the lungs of emphysema patients and mice with cigarette smoke extract (CSE)-induced emphysema. Such effects could be abrogated by silencing endogenous ProT expression. Collectively, our results uncover acetylated Smad7 regulated by ProT as an important determinant in dysregulated TGFβ signalling that contributes to emphysema pathogenesis., (Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
265. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
- Author
-
Su BH, Shieh GS, Tseng YL, Shiau AL, and Wu CL
- Subjects
- ATP Binding Cassette Transporter, Subfamily B genetics, Active Transport, Cell Nucleus, Adenocarcinoma genetics, Adenocarcinoma metabolism, Adenocarcinoma pathology, Adenocarcinoma virology, Adenocarcinoma of Lung, Adenoviridae growth & development, Adenovirus E1A Proteins genetics, Adenovirus E1A Proteins metabolism, Animals, Chemotherapy, Adjuvant, E2F1 Transcription Factor genetics, E2F1 Transcription Factor metabolism, Feasibility Studies, Gene Expression Regulation, Neoplastic, Gene Expression Regulation, Viral, HEK293 Cells, Homeostasis, Host-Pathogen Interactions, Humans, Lung Neoplasms genetics, Lung Neoplasms metabolism, Lung Neoplasms pathology, Lung Neoplasms virology, MCF-7 Cells, Mice, Inbred NOD, Mice, SCID, Oncolytic Viruses growth & development, Phosphorylation, Proto-Oncogene Proteins c-akt metabolism, Time Factors, Transcription, Genetic, Transfection, Virus Replication, Xenograft Model Antitumor Assays, Y-Box-Binding Protein 1 genetics, Y-Box-Binding Protein 1 metabolism, Adenocarcinoma therapy, Adenoviridae genetics, Antineoplastic Agents, Phytogenic pharmacology, Etoposide pharmacology, Lung Neoplasms therapy, Oncolytic Virotherapy methods, Oncolytic Viruses genetics, Promoter Regions, Genetic
- Abstract
Conditionally replicating adenoviruses (CRAds), or oncolytic adenoviruses, such as E1B55K-deleted adenovirus, are attractive anticancer agents. However, the therapeutic efficacy of E1B55K-deleted adenovirus for refractory solid tumors has been limited. Environmental stress conditions may induce nuclear accumulation of YB-1, which occurs in multidrug-resistant and adenovirus-infected cancer cells. Overexpression and nuclear localization of YB-1 are associated with poor prognosis and tumor recurrence in various cancers. Nuclear YB-1 transactivates the multidrug resistance 1 (MDR1) genes through the Y-box. Here, we developed a novel E1B55K-deleted adenovirus driven by the MDR1 promoter, designed Ad5GS3. We tested the feasibility of using YB-1 to transcriptionally regulate Ad5GS3 replication in cancer cells and thereby to enhance antitumor efficacy. We evaluated synergistic antitumor effects of oncolytic virotherapy in combination with chemotherapy. Our results show that adenovirus E1A induced E2F-1 activity to augment YB-1 expression, which shut down host protein synthesis in cancer cells during adenovirus replication. In cancer cells infected with Ad5WS1, an E1B55K-deleted adenovirus driven by the E1 promoter, E1A enhanced YB-1 expression, and then further phosphorylated Akt, which, in turn, triggered nuclear translocation of YB-1. Ad5GS3 in combination with chemotherapeutic agents facilitated nuclear localization of YB-1 and, in turn, upregulated the MDR1 promoter activity and enhanced Ad5GS3 replication in cancer cells. Thus, E1A, YB-1, and the MDR1 promoter form a positive feedback loop to promote Ad5GS3 replication in cancer cells, and this regulation can be further augmented when chemotherapeutic agents are added. In the in vivo study, Ad5GS3 in combination with etoposide synergistically suppressed tumor growth and prolonged survival in NOD/SCID mice bearing human lung tumor xenografts. More importantly, Ad5GS3 exerted potent oncolytic activity against clinical advanced lung adenocarcinoma, which was associated with elevated levels of nuclear YB-1 and cytoplasmic MDR1 expression in the advanced tumors. Therefore, Ad5GS3 may have therapeutic potential for cancer treatment, especially in combination with chemotherapy. Because YB-1 is expressed in a broad spectrum of cancers, this oncolytic adenovirus may be broadly applicable.
- Published
- 2015
- Full Text
- View/download PDF
266. Prothymosin-α Overexpression Contributes to the Development of Insulin Resistance.
- Author
-
Su YC, Ou HY, Wu HT, Wu P, Chen YC, Su BH, Shiau AL, Chang CJ, and Wu CL
- Subjects
- Aged, Animals, Diabetes Mellitus, Type 2 metabolism, Diet, High-Fat, Gene Silencing drug effects, Genetic Vectors, Glucose metabolism, Humans, Lentivirus genetics, Liver metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Muscle Fibers, Skeletal metabolism, NF-kappa B metabolism, RNA, Small Interfering genetics, RNA, Small Interfering pharmacology, Thymosin biosynthesis, Toll-Like Receptor 4 metabolism, Insulin Resistance physiology, Protein Precursors biosynthesis, Thymosin analogs & derivatives
- Abstract
Context: Prothymosin-α (ProT) is involved in oxidative stress, inflammation, cell proliferation, and apoptosis. Increased oxidative stress and chronic inflammation participate in the pathogenesis of diabetes. A recent study found that ProT is a ligand of toll-like receptor 4, which plays an important role in the development of insulin resistance. However, its physiological role remains poorly understood., Objective: The objective was to investigate whether ProT contributes to the development of insulin resistance., Design, Settings, and Patients: A total of 185 subjects were recruited and classified into nondiabetes (n = 95) and newly diagnosed diabetes (n = 90) groups. Transgenic mice overexpressing ProT were used to investigate the role of ProT in the development of insulin resistance. Lentiviral vectors carrying short hairpin RNA specific for ProT were delivered via the portal vein to silence hepatic ProT expression in mice with high-fat diet-induced insulin resistance. Glucose uptake was determined in L6 myotubes., Results: We show that the serum ProT levels of patients with type 2 diabetes were significantly higher than those of normal individuals (mean ± SEM, 419.8 ± 46.47 vs 246.4 ± 27.89 pg/mL; P < .001). Furthermore, ProT transgenic mice exhibited an insulin-resistant phenotype, whereas the silencing of hepatic ProT expression ameliorated high-fat diet-induced insulin resistance in C57BL/6 mice. In vitro studies reveal that ProT induced insulin resistance through a toll-like receptor 4-nuclear factor-κB-dependent pathway., Conclusions: Our results support the role for ProT in the development of insulin resistance. Therefore, ProT is a potential novel therapeutic target for type 2 diabetes.
- Published
- 2015
- Full Text
- View/download PDF
267. Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer.
- Author
-
Tsai YS, Jou YC, Tung CL, Lin CT, Shen CH, Chen SY, Tsai HT, Lai CL, Wu CL, and Tzai TS
- Subjects
- Aged, Biomarkers, Tumor immunology, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes pathology, Carcinoma, Transitional Cell immunology, Carcinoma, Transitional Cell pathology, Cell Nucleus metabolism, Disease Progression, Disease-Free Survival, Female, Forkhead Transcription Factors immunology, Forkhead Transcription Factors metabolism, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Male, Prognosis, Proportional Hazards Models, Protein Precursors analysis, Thymosin analysis, Thymosin biosynthesis, Urinary Bladder Neoplasms immunology, Urinary Bladder Neoplasms pathology, Biomarkers, Tumor analysis, Carcinoma, Transitional Cell metabolism, Lymphocytes, Tumor-Infiltrating pathology, Protein Precursors biosynthesis, Thymosin analogs & derivatives, Urinary Bladder Neoplasms metabolism
- Abstract
In this paper, we report a study on the clinical relevance of prothymosin-α expression and its correlation with intratumoral Foxp3(+) and CD8(+) lymphocytes (Foxp3(+)TIL and CD8(+)TIL) in bladder cancer patients. We used immunohistochemical staining for prothymosin-α, Foxp3, and CD8 on 101 tumor specimens harvested by endoscopic resection. The results were correlated with clinicopathological variables and clinical outcome in bladder cancer patients, particularly in 73 patients with superficial disease, using the log-rank test and Cox proportional hazard model. Overall, of the tumors, 30 % were negative, 34 % showed nuclear, and 37 % showed cytoplasmic prothymosin-α expression. Foxp3(+)TILs were detected in 11 % of patients (nonnuclear vs. nuclear, p = 0.096). Patients with a history of urothelial carcinoma have a higher frequency of nonnuclear prothymosin-α expression than those without (p = 0.016, chi-square test). By univariate and multivariate analyses of cases with superficial disease, grade and stage were identified as independent predictors for recurrence-free survival (p = 0.016 and 0.016, respectively). Higher stage and nonnuclear prothymosin-α expression independently predict shorter progression-free survival (p = 0.006 and 0.043, respectively). The presence of Foxp3(+)TILs was significantly associated with disease progression by univariate analysis (p = 0.022), but not by multivariate analysis (p = 0.147). In vitro assays showed that J82 cells which express ectopically nuclear prothymosin-α exhibit higher growth rate and secrete less TGF-β1 than those with cytoplasmic expression or control cells. Altogether, prothymosin-α expression is a determinant of disease progression in superficial bladder cancer. Foxp3(+)TILs tend to be found more often in bladder cancer with nonnuclear prothymosin-α expression. Future study is required to unravel their interaction.
- Published
- 2014
- Full Text
- View/download PDF
268. High-level β1-integrin expression in a subpopulation of highly tumorigenic oral cancer cells.
- Author
-
Lin HC, Wu CL, Chen YL, Huang JS, Wong TY, and Yuan K
- Subjects
- Animals, Carcinoma, Squamous Cell pathology, Heterografts, Humans, Integrin beta1 genetics, Mice, Mouth Neoplasms pathology, RNA, Small Interfering genetics, Carcinoma, Squamous Cell metabolism, Integrin beta1 metabolism, Mouth Neoplasms metabolism
- Abstract
Objectives: The β1 integrin (CD29) is a putative marker for cancerous epithelial stem cells. Cancer stem cells are essential to drive tumor growth, recurrence, and metastasis. We investigated the role of β1-integrin expression in the development of malignant phenotypes of oral squamous cell carcinoma (OSCC)., Materials and Methods: Immunostaining was used to analyze the expression levels of β1 integrins in different types of cell colonies and tumor spheres. The results of cell viability and migration assays with and without siRNA knockdown of β1-integrin expression were compared. Cells expressing β1 integrins were evaluated for their tumorigenicity in mice. The expression of β1 integrins in human specimens of oral cancers at different clinical stages was semiquantified based on immunohistochemical staining of the β1-integrin protein., Results: The expression level of β1 integrins in Meng-1 oral epidermoid carcinoma cells (OECM-1) cells was significantly higher in holoclonal colonies and tumor spheres compared to control cells. The knockdown of β1-integrin expression in OECM-1 cells reduced cell proliferation, migration, and tumor sphere formation. Beta-1 integrin (+) cells were more tumorigenic in the mouse xenograft model than β1 integrin (-) cells. In the human specimens, the expression level of the β1-integrin protein positively correlated with the clinical stage., Conclusion: The expression of β1 integrin in OECM-1 cells is involved in the development of malignant phenotypes of OSCC., Clinical Relevance: Inhibitors for β1-integrin signaling may be suitable to become target-specific therapies for OSCC.
- Published
- 2014
- Full Text
- View/download PDF
269. MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells.
- Author
-
Feng YH, Wu CL, Shiau AL, Lee JC, Chang JG, Lu PJ, Tung CL, Feng LY, Huang WT, and Tsao CJ
- Subjects
- Cell Movement, Cell Proliferation, Colonic Neoplasms genetics, Colonic Neoplasms metabolism, Gene Expression Regulation, Neoplastic, HCT116 Cells, Humans, Intracellular Signaling Peptides and Proteins metabolism, Membrane Proteins, MicroRNAs metabolism, PTEN Phosphohydrolase genetics, PTEN Phosphohydrolase metabolism, Up-Regulation, Antimetabolites, Antineoplastic pharmacology, Colonic Neoplasms drug therapy, Fluorouracil pharmacology, Hypoglycemic Agents pharmacology, Intracellular Signaling Peptides and Proteins genetics, Metformin pharmacology, MicroRNAs genetics
- Abstract
Sprouty2 (Spry2) was identified recently as a tumor suppressor gene in cancer cells which inhibits the activation of receptor tyrosine kinases (RTKs). The present study explored the effect of Spry2 in colon cancer cells in order to assess its potential use in the treatment of colon cancer. Expression of Spry2 inhibited the growth of a colon cancer cell line, HCT116, and induced sensitization to fluorouracil (5-FU) and metformin. Spry2 promoted apoptosis of cancer cells in association with activation of the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) pathway and the blockade of Ras-Raf-Erk signaling. Treatment of Spry2-HCT116 cells with metformin resulted in a more prominent effect on the inhibition of cell migration. Inhibition of microRNA-21 (mir‑21) induced upregulation of Spry2 and PTEN which underscores the importance of mir-21 in Spry2-associated tumorigenesis of the colon. These results point toward a potential strategy for colon cancer treatment worthy of further investigation.
- Published
- 2012
- Full Text
- View/download PDF
270. Multivalent structure of galectin-1-nanogold complex serves as potential therapeutics for rheumatoid arthritis by enhancing receptor clustering.
- Author
-
Huang YJ, Shiau AL, Chen SY, Chen YL, Wang CR, Tsai CY, Chang MY, Li YT, Leu CH, and Wu CL
- Subjects
- Animals, Ankle Joint diagnostic imaging, Ankle Joint pathology, Arthritis, Experimental chemically induced, Arthritis, Experimental diagnostic imaging, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes metabolism, Cell Survival drug effects, Cells, Cultured, Cytokines drug effects, Cytokines metabolism, Galectin 1 chemistry, Gold chemistry, Humans, Injections, Intra-Articular, Jurkat Cells drug effects, Jurkat Cells metabolism, Male, Metal Nanoparticles chemistry, Radiography, Rats, Rats, Sprague-Dawley, Receptors, Cell Surface metabolism, Apoptosis drug effects, Arthritis, Experimental drug therapy, Galectin 1 administration & dosage, Gold administration & dosage, Metal Nanoparticles administration & dosage, Receptors, Cell Surface drug effects
- Abstract
Cellular behaviour is controlled by numerous processes, including intracellular signalling pathways that are triggered by the binding of ligands with cell surface receptors. Multivalent ligands have multiple copies of a recognition element that binds to receptors and influences downstream signals. Nanoparticle-ligand complexes may form multivalent structures to crosslink receptors with high avidity and specificity. After conjugation onto gold nanoparticles, galectin-1 (Au-Gal1) bound with higher affinity to Jurkat cells to promote CD45 clustering and inhibition of its phosphatase activity, resulting in enhancement of apoptosis via caspase-dependent pathways. Au-Gal1 injected intra-articularly into rats with collagen-induced arthritis (CIA) promoted apoptosis of CD4+ T cells and reduced pro-inflammatory cytokine levels in the ankle joints as well as ameliorated clinical symptoms of arthritis. These observed therapeutic effects indicate that the multivalent structure of nanoparticle-ligands can regulate the distribution of cell surface receptors and subsequent intracellular signalling, and this may provide new insights into nanoparticle applications.
- Published
- 2012
- Full Text
- View/download PDF
271. T cell augments the antitumor activity of tumor-targeting Salmonella.
- Author
-
Lee CH, Hsieh JL, Wu CL, Hsu PY, and Shiau AL
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Cell Line, Tumor, Disease Models, Animal, Humans, Immunotherapy, Male, Mice, Mice, Inbred C57BL, Neoplasms immunology, Salmonella Infections microbiology, Salmonella enterica physiology, Xenograft Model Antitumor Assays, Antineoplastic Agents immunology, Biological Therapy, CD4-Positive T-Lymphocytes immunology, Neoplasms microbiology, Neoplasms therapy, Salmonella Infections immunology, Salmonella enterica immunology
- Abstract
Systemic administration of Salmonella to tumor-bearing mice leads to preferential accumulation within tumor sites and retardation of tumor growth. However, the detailed mechanism of Salmonella-induced antitumor immune response via host T cell remains uncertain. Herein, we used wild-type, CD4(+) T-cell-deficient, and CD8(+) T-cell-deficient mice to study the role of T cell in the antitumor immune responses induced by Salmonella enterica serovar Choleraesuis (Salmonella Choleraesuis). When systemically administered into mice bearing tumors, Salmonella Choleraesuis significantly inhibited tumor growth by 50%. In contrast, in T-cell-deficient mice, there was only 34-42% inhibition of tumor growth. We found that treatment with Salmonella Choleraesuis significantly upregulates interferon-γ in wild-type and CD8(+) T-cell-deficient mice, but not in CD4(+) T-cell-deficient mice. Furthermore, immunohistochemical staining of the tumors revealed more infiltration of macrophages and neutrophils in wild-type mice after Salmonella Choleraesuis treatment compared with those in T-cell-deficient mice. The antitumor therapeutic effect mediated by Salmonella Choleraesuis is associated with an inflammatory immune response at the tumor site and a tumor T helper 1-type immune response. In conclusion, these results suggest that tumor-targeted therapy using Salmonella Choleraesuis, which exerts tumoricidal effects and stimulates T cell activities, represents a potential strategy for the treatment of tumor.
- Published
- 2011
- Full Text
- View/download PDF
272. Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells.
- Author
-
Feng YH, Tsao CJ, Wu CL, Chang JG, Lu PJ, Yeh KT, Shieh GS, Shiau AL, and Lee JC
- Subjects
- Animals, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized, Antineoplastic Agents pharmacology, Cell Survival drug effects, Cetuximab, Colonic Neoplasms metabolism, Colonic Neoplasms pathology, ErbB Receptors genetics, Female, Gefitinib, HCT116 Cells, HT29 Cells, Humans, Immunoblotting, Intracellular Signaling Peptides and Proteins genetics, Membrane Proteins, Mice, Mice, Inbred BALB C, Mice, Nude, PTEN Phosphohydrolase genetics, PTEN Phosphohydrolase metabolism, Phosphorylation drug effects, Protein Kinase Inhibitors pharmacology, RNA Interference, Reverse Transcriptase Polymerase Chain Reaction, Xenograft Model Antitumor Assays, Colonic Neoplasms drug therapy, ErbB Receptors metabolism, Intracellular Signaling Peptides and Proteins metabolism, Quinazolines pharmacology
- Abstract
Sprouty2 (Spry2) is known to increase the expression of epidermal growth factor receptors (EGFR) by conjugating with c-Casitas B-lineage lymphoma (C-Cbl) to decrease protein degradation. The effect of Spry2 on the treatment of gefitinib, a tyrosine kinase inhibitor of EGFR, with regards to colon cancer is still unclear. The half maximal inhibitory concentration (IC50) values of gefitinib in six colon cancer cell lines were assessed. HCT116 and C2BBel cells expressed lower levels of Spry2 protein and were less sensitive to gefitinib, whereas HT29 cells that expressed high levels of Spry2 protein were more sensitive to gefitinib. The sensitivity to gefitinib was increased after overexpression of Spry2 in HCT116 cells, whereas it was decreased after Spry2 knockdown in HT29 cells. The levels of both phosphorylated and total EGFR were increased when HCT116 cells ectopically overexpressed Spry2, with concomitant increase in phosphatase and tensin homolog (PTEN) expression. Inhibition of EGFR by cetuximab reduced sensitivity to gefitinib in HCT116 cells overexpressing Spry2. However, knockdown of PTEN or K-ras failed to diminish the effect of Spry2 on gefitinib sensitivity. Of note, Spry2 enhanced the antitumor effect of gefitinib in a xenograft model of HCT116 tumors, which harbored K-ras codon 13 mutation. In conclusion, Spry2 can enhance the response of colon cancer cells to gefitinib by increasing the expression of phosphorylated and total EGFR. These results suggest that Spry2 may be a potential biomarker in predicting the response to anti-EGFR treatment in colon cancer and that it is necessary to conduct clinical studies to incorporate Spry2 into the network of cancer treatment., (© 2010 Japanese Cancer Association.)
- Published
- 2010
- Full Text
- View/download PDF
273. The Akt-endothelial nitric oxide synthase pathway in lipopolysaccharide preconditioning-induced hypoxic-ischemic tolerance in the neonatal rat brain.
- Author
-
Lin HY, Wu CL, and Huang CC
- Subjects
- Animals, Animals, Newborn, Brain drug effects, Brain pathology, Female, Hypoxia-Ischemia, Brain metabolism, Hypoxia-Ischemia, Brain pathology, Lipopolysaccharides pharmacology, Nitric Oxide Synthase Type III biosynthesis, Rats, Rats, Sprague-Dawley, Signal Transduction drug effects, Brain metabolism, Hypoxia-Ischemia, Brain prevention & control, Ischemic Preconditioning methods, Nitric Oxide Synthase Type III physiology, Proto-Oncogene Proteins c-akt physiology, Signal Transduction physiology
- Abstract
Background and Purpose: Low-dose lipopolysaccharide (LPS) preconditioning provides neonatal rats long-term neuroprotection against hypoxic ischemia (HI). Upregulating endothelial nitric oxide synthase (eNOS) protects against cerebral ischemia; however, whether eNOS is required for LPS preconditioning-induced protection in neonatal rats is unknown. We hypothesized that Akt activation, which upregulates eNOS in neurons and endothelial cells, is required for LPS preconditioning-induced tolerance against HI in the neonatal brain., Methods: Six-day-old rat pups were intraperitoneally injected with LPS (0.05 mg/kg) or normal saline 24 hours before HI. Immunoblotting and immunohistochemistry were used to determine the phospho-Akt (pAkt Ser473), phospho-eNOS (peNOS Ser1177), and eNOS levels and immunofluorescence to determine the cellular distribution of eNOS and pAkt Ser473. Pharmacological and genetic approaches were used to regulate Akt and eNOS, and the weight loss of cerebral hemispheres on postnatal Day 21 was used to assess outcomes., Results: eNOS, peNOS (Ser1177), and pAkt (Ser473) levels were significantly higher in LPS- than in normal saline-treated rats 24 hours postinjection. LPS-induced eNOS was expressed primarily in neurons and vascular endothelial cells. N-omega(omega)-nitro-L-arginine and antisense oligodeoxynucleotide treatment significantly reduced eNOS expression in neurons and endothelial cells and inhibited LPS-induced protection against HI in rat pups. L-arginine and adenovirus eNOS transfection upregulated eNOS and protected the rat pups against HI. Wortmannin treatment before LPS preconditioning significantly reduced eNOS expression in neurons and endothelial cells, which inhibited LPS-induced protection against HI., Conclusions: Akt-mediated eNOS upregulation in neurons and vascular endothelial cells is required for LPS-induced tolerance against HI in the neonatal rat brain.
- Published
- 2010
- Full Text
- View/download PDF
274. Amelioration of experimental arthritis by a telomerase-dependent conditionally replicating adenovirus that targets synovial fibroblasts.
- Author
-
Chen SY, Shiau AL, Shieh GS, Su CH, Lee CH, Lee HL, Wang CR, and Wu CL
- Subjects
- Adenoviridae genetics, Adenovirus E1B Proteins genetics, Adenovirus E1B Proteins metabolism, Animals, Arthritis, Experimental metabolism, Arthritis, Rheumatoid metabolism, Arthritis, Rheumatoid pathology, Arthritis, Rheumatoid therapy, Cell Line, Cell Line, Tumor, Disease Models, Animal, Fibroblasts metabolism, Gene Deletion, Humans, Interleukin-1beta metabolism, Matrix Metalloproteinase 9 metabolism, Procollagen-Proline Dioxygenase metabolism, Promoter Regions, Genetic genetics, Promoter Regions, Genetic physiology, Rats, Rats, Sprague-Dawley, Receptors, Virus metabolism, Synovial Membrane metabolism, Telomerase genetics, Telomerase metabolism, Adenoviridae physiology, Arthritis, Experimental pathology, Arthritis, Experimental therapy, Fibroblasts pathology, Synovial Membrane pathology, Telomerase physiology, Virus Replication physiology
- Abstract
Objective: Synovial fibroblasts (SFs) play a pivotal role in the pathogenesis of rheumatoid arthritis (RA). It has been documented that the phenotype of rheumatoid synovium is similar, in many respects, to that of an aggressive tumor. In this study, a novel, genetically engineered adenovirus was designed to lyse SFs that exhibit high telomerase activity and p53 mutations, and its effects as a novel therapeutic strategy were assessed in an experimental arthritis model., Methods: An E1B-55-kd-deleted adenovirus driven by the human telomerase reverse transcriptase promoter was constructed (designated Ad.GS1). Cytolysis of SFs and productive replication of Ad.GS1 in the SFs of rats with collagen-induced arthritis (CIA), as well as the SFs of patients with RA (RASFs), were assessed in vitro and in vivo. Treatment responses, as well as the presence of disease-related cytokines and enzymes in the ankle joints, were determined in the murine model., Results: Ad.GS1 replicated in and induced cytolysis of human RASFs and SFs from arthritic rats, but spared normal fibroblasts. Bioluminescence imaging in vivo also demonstrated replication of Ad.GS1 in arthritic rat joints, but not in normal rat joints. Intraarticular administration of Ad.GS1 significantly reduced the ankle circumference, articular index scores, radiographic scores, and histologic scores and decreased the production of interleukin-1beta, matrix metalloproteinase 9, and prolyl 4-hydroxylase in rats with CIA compared with their control counterparts., Conclusion: This study is the first to demonstrate the amelioration of arthritic symptoms by a novel, telomerase-dependent adenovirus in the rat CIA model, an experimental model that resembles human RA. In addition, the results suggest that because of its ability to induce cytolysis of SFs, this virus may be further explored as a therapeutic agent in patients with RA.
- Published
- 2009
- Full Text
- View/download PDF
275. Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma.
- Author
-
Hsieh JL, Lee CH, Teo ML, Lin YJ, Huang YS, Wu CL, and Shiau AL
- Subjects
- Adenoviridae genetics, Adenovirus E1A Proteins genetics, Adenovirus E1B Proteins deficiency, Adenovirus E1B Proteins genetics, Animals, Antineoplastic Agents pharmacology, Ascites pathology, Ascites virology, Carcinoma, Hepatocellular virology, Cisplatin pharmacology, Combined Modality Therapy, Female, Humans, Liver Neoplasms virology, Mice, Oncolytic Viruses genetics, Promoter Regions, Genetic, Carcinoma, Hepatocellular therapy, Liver Neoplasms therapy, Oncolytic Virotherapy methods, Prealbumin genetics
- Abstract
Strategies to increase antitumor efficacy of oncolytic adenoviruses are actively investigated. We have previously shown that E1B-55 kDa-deleted adenovirus, designated Ad5WS1, has therapeutic potential for treating hepatocellular carcinoma (HCC). To achieve HCC-restricted replication of oncolytic adenovirus, we generated Ad5WS2, an E1B-55 kDa-deleted adenovirus with its E1A gene driven by the liver-specific transthyretin promoter. Our results showed that Ad5WS2 could replicate within tumor cells where the transthyretin gene was expressed. Mouse transthyretin promoter was active in murine and human HCC cells, but relatively quiescent in cells of non-liver origin. Ad5WS2 caused severe cytolytic effect on HCC cells, but was much attenuated in non-HCC cells. Peritoneal administration of Ad5WS2 into mice bearing liver tumors grown in ascites resulted in enhanced survival. In an orthotopic HCC model, Ad5WS2, when systemically administered, exerted higher antitumor effects than Ad5WS1. Lack of viral replication in normal organs and minimal hepatic toxicity was noted after Ad5WS2 treatment. Furthermore, the antitumor effect of Ad5WS2 could be enhanced when combined with chemotherapeutic agent cisplatin in the ascites tumor model. These results suggest that E1B-55 kDa-deleted adenovirus driven by the transthyretin promoter may be a safer and more efficacious oncolytic agent for the treatment of primary and metastatic HCC.
- Published
- 2009
- Full Text
- View/download PDF
276. In vitro benzyl alcohol cytotoxicity: implications for intravitreal use of triamcinolone acetonide.
- Author
-
Chang YS, Wu CL, Tseng SH, Kuo PY, and Tseng SY
- Subjects
- Animals, Apoptosis drug effects, Cell Death drug effects, Cell Shape drug effects, Cell Size drug effects, Cells, Cultured, DNA Damage, Humans, Microscopy, Electron, Necrosis, Pigment Epithelium of Eye pathology, Pigment Epithelium of Eye ultrastructure, Rabbits, Trypan Blue, Benzyl Alcohol toxicity, Pigment Epithelium of Eye drug effects, Preservatives, Pharmaceutical toxicity, Triamcinolone Acetonide
- Abstract
The aim of the study was to investigate the toxicity of benzyl alcohol (BA), the preservative in commercial triamcinolone acetonide (TA) suspensions, on retinal pigment epithelial (RPE) cells. Cultured RPE cells from a human cell line (ARPE-19) and from rabbits were exposed to the balanced salt solution (control) or BA (0.0225, 0.225, 0.9, 3 or 9mg/mL) for 5, 30, 60, or 120min. Morphological changes of RPE cells were evaluated by the trypan blue in situ staining. The proportions of dead cells were quantitatively measured by the trypan blue exclusion assay, and those of functional cells were assessed by a mitochondrial dehydrogenase assay. The mechanism of cytotoxicity was determined by the acridine orange/ethidium bromide staining and DNA laddering technique. Furthermore, ultrastructural changes were observed by transmission electron microscopy. The results showed that RPE cell damage was dose- and time-dependent. BA 0.225mg/mL, the clinically relevant concentration in TA following intravitreal injection, caused ultrastructural damage and impaired human RPE cell function at 2h; but BA 0.0225mg/mL did not. BA 9.0mg/mL, the concentration in commercial TA suspensions, was toxic within 5min on each assay for both human and rabbit RPE cells. The major mechanism of cell death was necrosis. In conclusion, BA in commercial TA suspensions injected intravitreally (0.225-9mg/mL) can damage RPE cells. Our in vitro study on benzyl alcohol cytotoxicity has significant clinical implications for intravitreal use of TA. We suggest that, before a commercial TA solution is used intravitreally, the vehicle should be removed to prevent damaging the RPE layer, particularly during macular hole surgery. Commercial development of a preservative-free TA suspension for intraocular use is urged.
- Published
- 2008
- Full Text
- View/download PDF
277. Prothymosin alpha lacking the nuclear localization signal as an effective gene therapeutic strategy in collagen-induced arthritis.
- Author
-
Shiau AL, Chen SY, Chang MY, Su CH, Chung SY, Yo YT, Wang CR, and Wu CL
- Subjects
- Adenoviridae genetics, Animals, Ankle Joint immunology, Ankle Joint pathology, Arthritis, Rheumatoid chemically induced, Arthritis, Rheumatoid pathology, Cell Proliferation, Chemokine CCL3, Chemokine CCL4, Chemotaxis, Collagen toxicity, Fibroblasts, Humans, Interleukin-1beta metabolism, Macrophage Inflammatory Proteins metabolism, Macrophages immunology, Matrix Metalloproteinase 2 metabolism, Matrix Metalloproteinase 9 metabolism, Nuclear Localization Signals analysis, Protein Precursors analysis, Rats, Sequence Deletion, Synovial Fluid chemistry, Thymosin analysis, Thymosin genetics, Tumor Necrosis Factor-alpha metabolism, Up-Regulation, Arthritis, Rheumatoid therapy, Genetic Therapy, Genetic Vectors administration & dosage, Genetic Vectors genetics, Nuclear Localization Signals genetics, Protein Precursors genetics, Thymosin analogs & derivatives
- Abstract
Prothymosin alpha (ProT) is regulated by c-Myc, an oncoprotein overexpressed in synovium of rheumatoid arthritis, and is associated with cell proliferation. However, ProT also exerts immunomodulatory activities. The growth-promoting activity of ProT can be abolished by deleting its nuclear localization signal (NLS). In this study, we showed that AdProTDeltaNLS, an adenoviral vector encoding ProT lacking the NLS, did not enhance the proliferation of synovial fibroblasts. AdProTDeltaNLS treatment abolished the up-regulation of the MIP-1alpha promoter activity induced by TNF-alpha in synovial fibroblasts. AdProTDeltaNLS suppressed macrophage chemotaxis and reduced macrophage infiltration into the ankle joints in rats with collagen-induced arthritis (CIA). Neutralization test confirmed the involvement of MIP-1alpha in macrophage chemotaxis. Administration of AdProTDeltaNLS reduced the severity of CIA in the clinical, radiographic, and histological aspects. The levels of TNF-alpha (mean +/- SEM, 1261.9 +/- 107.9 vs 2880.1 +/- 561.4 pg/mg total protein; p < 0.05), IL-1beta (56.8 +/- 8.0 vs 109.2 +/- 4.9 pg/mg total protein; p < 0.01), and MIP-1alpha (41.7 +/- 3.6 vs 55.2 +/- 1.1 pg/mg total protein; p < 0.05) in the ankle joints were lower in the AdProTDeltaNLS-treated rats with CIA than those in their control counterparts. In the AdProTDeltaNLS-treated ankle joints, matrix metalloproteinase-9 expression was decreased by 40% and infiltrating macrophages reduced by 50%. Our results demonstrate that intra-articular delivery of AdProTDeltaNLS significantly ameliorated the clinical course of CIA in rats. This study is the first to suggest that ProT lacking the NLS may have therapeutic potential for the management of rheumatoid arthritis.
- Published
- 2007
- Full Text
- View/download PDF
278. Transgenic overexpression of prothymosin alpha induces development of polycystic kidney disease.
- Author
-
Li KJ, Shiau AL, Chiou YY, Yo YT, and Wu CL
- Subjects
- Animals, Base Sequence, Blood Urea Nitrogen, DNA, Complementary genetics, Disease Models, Animal, ErbB Receptors genetics, Gene Expression, Humans, Kidney immunology, Kidney metabolism, Kidney pathology, Mice, Mice, Transgenic, Phenotype, Polycystic Kidney Diseases metabolism, Polycystic Kidney Diseases pathology, Protein Precursors metabolism, Thymosin metabolism, Polycystic Kidney Diseases etiology, Polycystic Kidney Diseases genetics, Protein Precursors genetics, Thymosin analogs & derivatives, Thymosin genetics
- Abstract
Background: Polycystic kidney disease (PKD) is a genetic disorder characterized by development of renal cysts and progressive renal dysfunction. Renal tissues from both PKD patients and rodent models of PKD show elevated c-myc expression. Prothymosin alpha (ProT) is positively regulated by c-myc through binding to the E box of its promoter. Through creating transgenic mice and clinical studies, we sought to investigate whether ProT overexpression contributes to PKD development., Methods: ProT heterozygous and homozygous transgenic mice were generated and characterized. Morphologic, histologic, immunohistochemical, and biochemical analyses of the transgenic mice were performed., Results: Two transgenic lines that represented integration at two different loci of the chromosomes were generated. ProT overexpression in the kidneys of homozygous transgenic mice induced a PKD phenotype, which included polycystic kidneys, elevated blood urea nitrogen (BUN), and lethality at about 10 days of age. Similar overexpression pattern of ProT was noted in cystic kidneys of the transgenic mice as well as in human autosomal-recessive PKD (ARPKD) and autosomal-dominant PKD (ADPKD) kidneys. ProT protein levels in the kidneys and urine as well as renal mRNA level of epithelial growth factor receptor (EGFR) of homozygous ProT transgenic mice were significantly higher than heterozygous or nontransgenic littermates. Furthermore, the heterozygous transgenic mice at 17 months of age also developed mild cystic kidneys., Conclusion: Transgenic mice overexpressing ProT represent a novel model for PKD and may provide insights into PKD development. ProT, like c-myc and EGFR, may contribute to the development of renal cysts and may be a potential noninvasive diagnostic molecule of PKD.
- Published
- 2005
- Full Text
- View/download PDF
279. Characterization of aqueous dispersions of Fe(3)O(4) nanoparticles and their biomedical applications.
- Author
-
Cheng FY, Su CH, Yang YS, Yeh CS, Tsai CY, Wu CL, Wu MT, and Shieh DB
- Subjects
- Animals, Biomedical Engineering methods, COS Cells, Chlorocebus aethiops, Colloids chemistry, Ferric Compounds toxicity, Hemolysis drug effects, Humans, Nanotubes toxicity, Particle Size, Biocompatible Materials chemistry, Ferric Compounds chemistry, Materials Testing, Nanotubes chemistry, Nanotubes ultrastructure, Water chemistry
- Abstract
A newly developed non-polymer coated Fe(3)O(4) nanoparticles showing well-dispersion were synthesized using Fe(II) and Fe(III) salt chemical coprecipitation with tetramethylammonium hydroxide (N(CH(3))(4)OH) in an aqueous solution. Transmission electron microscopy (TEM), X-ray diffraction (XRD), Fourier transform infrared spectrometer (FT-IR), X-ray photoelectron spectrometer (XPS) and superconducting quantum interference measurement device (SQUID) measurements were employed to investigate the iron oxide properties. The resulting iron oxide particles were manipulated to be as small as 9 nm diameter in size. Based on FT-IR and X-ray photoelectron spectrometer results, it is suggested that the surfaces of the magnetite (Fe(3)O(4)) particles are covered with hydroxide (-OH) groups incorporated with (CH(3))(4)N(+) through electrostatic interaction. The in vitro cytotoxicity test revealed that the magnetite particles exhibited excellent biocompatibility, suggesting that they may be further explored for biomedical applications. NMR measurements revealed significantly reduced water proton relaxation times T1 and T2. The MR images of the nanoparticles in water, serum, and whole blood were investigated using a 1.5 T clinical MR imager. Significant reduction of the background medium signal was achieved in the T2-weighted and the T2*-weighted sequence especially in the serum and whole blood. Combining the advantage of MRI signal contrast, the non-polymer-coated surface chemistry for distinct bioconjugation and the homogenous nanometer size for better controlled biodistribution, these preliminary experiments demonstrated the potential of the as-synthesized magnetite material in functional molecular imaging for biomedical research and clinical diagnosis.
- Published
- 2005
- Full Text
- View/download PDF
280. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model.
- Author
-
Lee CH, Wu CL, and Shiau AL
- Subjects
- Animals, Cell Proliferation, Disease Models, Animal, Gene Transfer Techniques, Genetic Vectors, Humans, Lac Operon physiology, Lung Neoplasms metabolism, Lung Neoplasms secondary, Lung Neoplasms therapy, Melanoma, Experimental metabolism, Melanoma, Experimental pathology, Mice, Mice, Inbred C57BL, Survival Rate, beta-Galactosidase metabolism, Gene Expression Regulation, Neoplastic, Genetic Therapy, Melanoma, Experimental therapy, Salmonella genetics, Thrombospondin 1 genetics, Transgenes physiology
- Abstract
Some anaerobic and facultative anaerobic bacteria have been used experimentally as anticancer agents because of their selective growth in the hypoxia regions of solid tumors after systemic administration. We have previously shown the feasibility of using attenuated Salmonella choleraesuis as a gene delivery vector. In this study, we exploited S. choleraesuis carrying thrombospondin-1 (TSP-1) gene for treating primary melanoma and experimental pulmonary metastasis in the syngeneic murine B16F10 melanoma model. Systemic administration of S. choleraesuis allowed targeted gene delivery to tumors. The bacteria accumulated preferentially in tumors over livers and spleens at ratios ranging from 1000:1 to 10,000:1. The level of transgene expression via S. choleraesuis-mediated gene transfer in tumors could reach more than 1800-fold higher than in livers and spleens. Notably, bacterial accumulation was also observed in the lungs with metastatic nodules, but not in healthy lungs. When administered into mice bearing subcutaneous or pulmonary metastatic melanomas, S. choleraesuis carrying TSP-1 gene significantly inhibited tumor growth and enhanced survival of the mice. Immunohistochemical studies in the tumors from these mice displayed decreased intratumoral microvessel density. Taken together, these findings suggest that TSP-1 gene therapy delivered by S. choleraesuis may be effective for the treatment of primary as well as metastatic melanomas.
- Published
- 2005
- Full Text
- View/download PDF
281. Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function.
- Author
-
Hsieh JL, Wu CL, Lee CH, and Shiau AL
- Subjects
- Adenovirus E1B Proteins metabolism, Animals, Cell Survival, Cytoplasm metabolism, Female, Humans, Immunoblotting, Liver cytology, Liver Neoplasms metabolism, Luciferases metabolism, Mice, Mice, Inbred BALB C, Microscopy, Fluorescence, Time Factors, Transcription, Genetic, Transgenes, Tumor Cells, Cultured, Tumor Suppressor Protein p53 metabolism, Viral Regulatory and Accessory Proteins, Adenoviridae genetics, Carcinoma, Hepatocellular therapy, Genes, p53, Trans-Activators metabolism
- Abstract
Replication-selective adenovirus has been reported to kill tumor cells and hold promise for cancer therapy. In this study, we constructed an E1B M(r) 55000-deleted adenovirus, designated Ad5WS1, and examined its cytolytic effect on human hepatocellular carcinoma (HCC) cell lines with various p53 status. The results show that Ad5WS1 lysed HCC cells lacking p53 transcription activity. However, this effect was not observed in cells harboring functional p53. Because loss of p53 transcription activity can be induced by binding to hepatitis B virus X protein (HBx), we generated HBx stable transfectants from Chang liver cells and examined their susceptibility to Ad5WS1-induced cytolysis. Expression of HBx in Chang liver cells changed the location of p53 from the nucleus to the cytoplasm, which mostly coincided with the location of HBx in the cytoplasm. Disruption of p53 transcription activity by HBx in Chang liver cells rendered them susceptible to infection with Ad5WS1. Furthermore, Ad5WS1 exerted antitumor effect, especially when combined with chemotherapeutic agent cisplatin, in BALB/c mice bearing HBx-expressing HCC. Our results suggest that E1B M(r) 55000-deleted adenovirus may have therapeutic potential for the treatment of HCC with loss of p53 transcription activity or with HBx expression.
- Published
- 2003
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.